Genistein

Moderate evidence for bone density and menopausal symptom relief; cancer prevention data is mixed and context-dependent.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Multiple RCTs show genistein can reduce bone loss in postmenopausal women. It modulates estrogen receptors and may have both estrogenic and anti-estrogenic effects depending on tissue type. Epidemiological data from Asian populations suggests protective effects, though supplementation trials are less consistent.

• May preserve bone mineral density in postmenopausal women
• Reduces hot flash frequency in some trials
• Antioxidant and anti-inflammatory properties

Typical doses range from 40-80 mg daily of aglycone genistein for bone and menopausal outcomes.

• Mild GI symptoms
• Theoretical concern for estrogen-sensitive conditions
• May affect thyroid function at very high doses

Controversial in estrogen-sensitive cancers. Should be avoided by those on tamoxifen or with ER-positive breast cancer without medical guidance.

Effects are dose- and context-dependent. Equol-producer status affects individual response. Most positive data is from postmenopausal women.

• Longevity40
• Immunity30